视网膜母细胞瘤房水VEGF-A的横断面特征分析
该横断面研究分析了60份房水样本(49只视网膜母细胞瘤眼54份,6份年龄匹配先天性白内障对照),用Olink PEA法测定VEGF-A浓度。结果显示治疗后VEGF-A显著低于治疗前(P < 0.001),次级眼球摘除样本高于治疗结束后6个月样本(P = 0.007),提示房水VEGF-A反映眼内微环境。
要点
- 视网膜母细胞瘤眼房水VEGF-A中位259 pg/mL,白内障对照中位149 pg/mL。
- 治疗后VEGF-A显著低于治疗前(P < 0.001)。
- 次级眼球摘除样本VEGF-A高于治疗结束后6个月样本(P = 0.007)。
核心结论
- 房水液体活检是视网膜母细胞瘤中VEGF-A的高产来源。
- VEGF-A浓度在初次眼球摘除时最高,治疗完成后趋于正常化。
- 房水VEGF-A反映眼内微环境,需进一步验证以理解其在疾病进展中的作用。
研究设计与样本
- 横断面研究,分析60份房水样本:49只视网膜母细胞瘤眼54份,6份年龄匹配先天性白内障对照。
- 治疗前视网膜母细胞瘤眼样本:保眼治疗前6份,初次眼球摘除后即刻5份。
- 治疗后眼样本:次级眼球摘除12份,活跃治疗中12份,治疗结束后6个月19份。
- VEGF-A用Olink邻位延伸法测定,报告为绝对浓度(pg/mL)。
主要发现
- 视网膜母细胞瘤队列VEGF-A中位259 pg/mL(95%CI = 140-423,IQR = 115-568),白内障对照中位149 pg/mL(95%CI = 39.8-318,IQR = 61.3-208)。
- 治疗后VEGF-A显著低于治疗前:中位182 pg/mL(95%CI = 121-310,IQR = 110-423)vs. 中位1380 pg/mL(95%CI = 278-18,100,IQR = 467-12,400),P < 0.001。
- 治疗眼中次级眼球摘除样本VEGF-A高于治疗结束后6个月样本:中位506 pg/mL(95%CI = 120-1010,IQR = 207-926)vs. 中位129 pg/mL(95%CI = 79.5-212,IQR = 79.5-212),P = 0.007。
临床怎么用
- 房水液体活检可作为视网膜母细胞瘤VEGF-A检测的高产来源。
- 房水VEGF-A动态变化可能反映眼内微环境及治疗反应,但需进一步验证后用于临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Vascular endothelial growth factor A (VEGF-A) is a key mediator of tumor angiogenesis. This cross-sectional study quantified aqueous humor (AH) VEGF-A in retinoblastoma (RB) eyes and retrospectively evaluated its association with clinical features. METHODS: This study analyzed 60 AH samples: 54 from 49 RB eyes and 6 from age-matched controls with congenital cataract. From pretreatment RB eyes, six samples were collected prior to globe-salvaging treatment and five immediately after primary enucleation (PE). From post-treatment eyes, 12 samples were collected at secondary enucleation (SE), 12 during active treatment (TX), and 19 at 6 months after treatment (END). VEGF-A was measured using the Olink Proximity Extension Assay and reported as absolute concentrations (pg/mL). RESULTS: VEGF-A concentrations (median and interquartile range [IQR]) were 259 (95% confidence interval [CI] = 140-423, IQR = 115-568) in the RB cohort, compared with 149 (95% CI = 39.8-318, IQR = 61.3-208) in cataract controls. Post-treatment levels were significantly lower than pretreatment levels (median = 182, 95% CI = 121-310, IQR = 110-423 vs. median = 1380, 95% CI = 278-18,100, IQR = 467-12,400, P < 0.001). Among treated eyes, SE samples had higher VEGF-A than END samples (median = 506, 95% CI = 120-1010, IQR = 207-926 vs. median = 129, 95% CI = 79.5-212, IQR = 79.5-212, P = 0.007). CONCLUSIONS: AH liquid biopsy was a high-yield source of VEGF-A in RB. VEGF-A concentrations were highest during primary enucleation and normalized after treatment completion. These findings support that aqueous VEGF-A reflects the intraocular microenvironment, warranting further validation to improve our understanding of its role in disease progression in RB.
引用
- Lin M, Peng CC, Reid M, et al. Cross-Sectional Profiling of Aqueous Humor VEGF-A Reflects the Tumor and Ocular Microenvironment in Retinoblastoma. Invest Ophthalmol Vis Sci. 2026. PMID: 42872949. doi:10.1167/iovs.67.12.23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。